The efficacy and safety of gemcitabine-based combination therapy vs. gemcitabine alone for the treatment of advanced pancreatic cancer: a systematic review and meta-analysis

BACKGROUND: Gemcitabine (GEM) is used as a standard first-line drug to effectively alleviate symptoms and prolong survival time for advanced pancreatic cancer. Most randomized controlled trials (RCTs) show that GEM-based combination therapy is better than GEM alone, while some RCTs have the opposite...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhaohuan, He, Shuling, Wang, Ping, Zhou, Yibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459213/
https://www.ncbi.nlm.nih.gov/pubmed/36092340
http://dx.doi.org/10.21037/jgo-22-624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459213/
https://www.ncbi.nlm.nih.gov/pubmed/36092340
http://dx.doi.org/10.21037/jgo-22-624

Ejemplares similares